CCHT(SZ:000661) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-10-22 01:05Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received the acceptance notice from the National Medical Products Administration for the clinical trial application of GenSci142 capsules, aimed at treating bacterial vaginosis [1][3]. Group 1: Drug Information - Product Name: GenSci142 capsules [1] - Application Type: Clinical trial for domestic production [1] - Indication: Bacterial vaginosis (BV), a common vaginal infection among women of childbearing age [1] - Current Treatment: Recommended antibiotics include nitroimidazoles (e.g., metronidazole) and clindamycin, but long-term control is inadequate [1] - Resistance Issues: Gardnerella bacteria can develop resistance to metronidazole, complicating treatment [1] Group 2: Product Advantages - GenSci142 capsules utilize recombinant lytic enzymes targeting Gardnerella bacteria, offering advantages such as rapid action, precise bactericidal effects, effective biofilm clearance, low resistance risk, and local safety [2]. Group 3: Company Impact - Successful clinical trial progress could enhance the company's business structure, optimize product offerings, and strengthen its competitive edge in strategic areas [3][4].